Instructions Lipin-Biolic lyophilized powder for solution preparation 500 mg bottle No. 1
Composition
Active ingredient: 1 vial or bottle contains lecithin standard (in terms of lecithin) - 500 mg;
Excipients: lactose.
Dosage form
Lyophilisate for emulsion.
Main physicochemical properties: amorphous mass of white or light yellow color with a characteristic odor.
Pharmacotherapeutic group
Drugs affecting the digestive system and metabolism. ATC code A16A X.
Pharmacological properties
Pharmacodynamics
LIPIN-BIOLIK® has an antihypoxic effect, promotes an increase in the rate of oxygen diffusion from the lungs to the blood and from the blood to the tissues, normalizes the processes of tissue respiration. Restores the functional activity of endothelial cells, synthesis and release of endothelial relaxation factor, improves microcirculation and rheological properties of blood. LIPIN-BIOLIK® inhibits the processes of lipid peroxidation in the blood and tissues, supports the activity of the body's antioxidant systems, exhibits a membrane protective effect, performs the function of a nonspecific detoxifier, and increases nonspecific immunity.
When administered by inhalation, LIPIN-BIOLIK® helps preserve pulmonary surfactant, which improves pulmonary and alveolar ventilation, and increases the rate of oxygen transport through biological membranes. LIPIN-BIOLIK® does not affect the functional state of organs and body systems, is non-toxic, and has no cumulative properties.
Pharmacokinetics
After intravenous administration, LIPIN-BIOLIK® as a liposomal composition circulates in the blood for up to 2 hours. The maximum accumulation of the drug is observed in the liver and spleen (up to 20%), which is achieved 5 minutes after administration and persists for 180-300 minutes. It is excreted in the urine and feces.
Indication
The drug should be used as part of complex therapy.
Pulmonology. Acute and chronic respiratory failure syndrome of any genesis in adults and children, including newborns with respiratory disorders associated with perinatal hypoxia and asphyxia during childbirth. Cardiology. Acute myocardial infarction and unstable angina. Gastroenterology. Acute and chronic active hepatitis, chronic non-calculous cholecystitis, cirrhosis of the liver, non-specific ulcerative colitis. Obstetrics. Late gestosis, intra-abdominal fetal hypoxia. Nephrology. Acute and chronic pyelonephritis, glomerulonephritis, diabetic nephropathy, polycystic kidney disease, renal failure.
Contraindication
Individual hypersensitivity to the components of the drug.
Interaction with other medicinal products and other types of interactions
It is possible to prescribe LIPIN-BIOLIK® in complex therapy with non-steroidal, cytostatic, choleretic and vitamin drugs, antibiotics.
Application features
The drug contains lactose, therefore patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use LIPIN-BIOLIK®.
The ability to influence the reaction speed when driving or working with mechanisms
Didn't study.
Use during pregnancy or breastfeeding
Used during pregnancy or breastfeeding.
Method of administration and doses
Use intravenously, by inhalation, orally and rectally.
Prepare the liposomal composition (emulsion) LIPIN-BIOLIK® immediately before use.
Preparation of liposomal composition (emulsion).
Keep the vial (bottle) at room temperature for 30 minutes, then add 50 ml of 0.9% sodium chloride solution for injection or infusion, pre-warmed to 36°C, to the lyophilisate contained in the vial (bottle). After that, shake the vial (bottle) for 2-3 minutes until a homogeneous white emulsion is formed.
Distilled or boiled water can be used to prepare LIPIN-BIOLIK® emulsion for internal and rectal use.
Pulmonology.
Preparation of a liposomal composition (emulsion) for inhalation use.
For inhalation use, LIPIN-BIOLIK® is prescribed at a dose of 10-15 mg/kg of body weight per inhalation 1-2 times a day. The course of treatment is 5-10 days. It is possible to connect the inhaler to the respiratory circuit of the artificial lung ventilation (AVL). For inhalation, ultrasonic inhalers or aerosol-type inhalers must be used. The use of vapor-aerosol inhalers is unacceptable! In severe cases, the drug should be administered at a rate of 10-15 mg/kg of body weight 1-3 times a day. Newborns with respiratory distress syndrome should use LIPIN-BIOLIK® in the form of inhalations in doses of 25-100 mg/kg of body weight 3-4 times a day. The optimal duration of inhalation is 3-4 minutes. The course of treatment is 4-5 days. If necessary, the course of treatment can be extended to 10-12 days.
It is recommended to use inhalers and nebulizers. Before use, remove the inhaler from the packaging and allow it to warm to room temperature.
Pour the required amount of emulsion using a sterile syringe or directly from the vial (bottle) into the nebulizer chamber and close the lid. Connect the nebulizer chamber to the ventilator or compressor using an oxygen tube. Connect the T-shaped adapter to the nebulizer chamber. Connect the appropriate attachments to the T-shaped adapter (nasal cannulas, respiratory masks for children and adults, mouthpieces, intubation tubes). It is recommended to use a nebulizer filling volume of 2-5 ml, a flow of "working" gas of 6-8 l/min. Inhalation is carried out until the calculated dose is consumed.
Cardiology.
In the treatment of acute myocardial infarction and unstable angina, LIPIN-BIOLIK® is prescribed at a dose of 35 mg/kg of body weight 4 times a day. The drug should be administered slowly. The course of treatment is 4-5 days.
When performing thrombolytic therapy to prevent the occurrence of myocardial reperfusion injuries, LIPIN-BIOLIK® should be administered at a dose of 30 mg/kg of body weight 30 minutes before the use of the thrombolytic, and then at a dose of 15 mg/kg of body weight 4 times a day. The course of treatment is 7-9 days.
Obstetrics.
When treating late gestosis, LIPIN-BIOLIK® should be prescribed at a dose of 5-10 mg/kg of body weight once a day.
The drug should be administered slowly. The course of treatment is 3-10 days, depending on the clinical manifestations of gestosis.
Gastroenterology.
In the treatment of acute or chronic active hepatitis, chronic non-calculous cholecystitis and liver cirrhosis, LIPIN-BIOLIK® is administered orally at a dose of 1 g 2 times a day. The course of treatment is 18-21 days. In case of severe disease, LIPIN-BIOLIK® is dissolved in 0.9% sodium chloride solution or infusions and administered intravenously drip at a dose of 1 g 2 times a day for 10 days. During the treatment, the method of administration of the drug may change. In the treatment of non-specific ulcerative colitis, LIPIN-BIOLIK® is administered at a dose of 1 g in the form of micro-enemas 2 times a day for 10 days, and then at a dose of 0.5 g 2 times a day for another 10 days.
Nephrology.
In the treatment of acute and chronic pyelonephritis, LIPIN-BIOLIK® is prescribed at a dose of 10-20 mg/kg of body weight once a day as part of combined antibacterial therapy. The drug is administered intravenously drip, slowly. The course of treatment is 3-4 days. In the treatment of chronic glomerulonephritis, pyelonephritis, diabetic nephropathy at the stage of chronic renal failure, LIPIN-BIOLIK® is prescribed at a dose of 10-20 mg/kg of body weight once a day in combination with standard basic therapy. The drug is administered intravenously drip, slowly. The course of treatment is 14 days.
Children
Used for children from birth.
Overdose
Possible manifestations of hypersensitivity to the components of the drug.
Treatment is symptomatic.
Adverse reactions
The drug in therapeutic doses is well tolerated by patients.
On the part of the immune system: allergic reactions.
From the nervous system: headache, dizziness.
Cardiac disorders: palpitations.
Vascular: decreased blood pressure.
Gastrointestinal: vomiting.
Skin and subcutaneous tissue disorders: urticaria, itching.
General disorders and administration site reactions: fever, weakness, pain in the lumbar spine, tremor of the limbs, shooting pain in the thoracic and lumbar spine, pain along the vein.
In these cases, the drug should be discontinued and symptomatic treatment should be prescribed.
Expiration date
1 year 6 months.
Storage conditions
Store in the freezer at temperatures from minus 20°C to minus 10°C.
Keep out of reach of children.
Packaging
500 mg in a vial or bottle No. 1; or set: three vials of 500 mg with one NEBULISER inhaler.
Vacation category
According to the recipe.
Producer
JSC "BIOLIK".
Location of the manufacturer and its business address
JSC "BIOLIK".
Kharkiv region, Kharkiv city, Pomirky.
